The role of central alpha-i adrenergic receptors 
Introduction
Human narcolepsy is a disabling sleep disorder of unknown origin, characterized by sudden attacks of partial or complete flaccid paralysis (cataplexy) and excessive daytime sleepiness. These attacks can strike spontaneously or be elicited by emotional experiences such as laughter, excitement, or fear. Sleep recording studies in narcoleptic patients show an abnormally rapid transition from wake to rapid eye movement (REM)' sleep during the day and a drastically shortened REM latency at night (1) . Since a state of muscular paralysis similar to cataplexy normally occurs during REM sleep, narcolepsy is considered an REM sleep disorder (1) .
Considerable attention has centered on the role of central cholinergic systems in the regulation of REM sleep. Cataplexy and REM sleep are controlled by known cholinergic mechanisms located in the brainstem (2) (3) (4) (5) (6) (7) . Cholinergic neurons of the dorsal pontine tegmentum tonically inhibit muscle tone during REM sleep. This muscle inhibition involves projections to the reticular formation in the medial medulla and from there to motor neurons in the spinal cord (2) (3) (4) (5) (6) (7) . Consistent with these anatomical findings, central cholinergic stimulation by physostigmine or arecoline has been reported to aggravate the symptoms in narcoleptic dogs, whereas central anticholinergic drugs, such as atropine or scopolamine, improve them (8) . The use of anticholinergic drugs has, however, been very disappointing in human narcolepsy, particularly because of their numerous side effects.
The pharmacological manipulations of the central cholinergic network have been coupled with investigations ofthe role of monoamines in controlling REM sleep (9) (10) (11) and cataplexy. Noncholinergic, monoaminergic (especially norepinephrine) reuptake blockers (tricyclic antidepressants, viloxazine, and nisoxetine) and monoamine-releasing drugs (amphetamine and methylphenidate) are REM sleep suppressants and have beneficial effects in human and canine narcolepsy (8) . However, it is difficult to assess which of their multiple pharmacological actions is responsible for their therapeutic effect and/or side effects. All these drugs act presynaptically on monoaminergic systems, and supposedly increase norepinephrine levels in the synaptic cleft. If such an increase in norepinephrine takes place, a postsynaptic adrenoceptor stimulation should occur, and such stimulation is probably involved in the therapeutic effects seen in narcoleptics.
Reports of changes in REM sleep in animals (12) (13) (14) (15) and humans (16) after treatment with alpha-1 adrenergic agents (increase with blockade and decrease with stimulation) provided further rationale for our hypothesis. The role of central alpha-1 mechanisms in narcolepsy was examined by in vivo pharmacology in narcoleptic Doberman pinschers, an autosomal recessive animal model of human narcolepsy (8, (17) (18) (19) . (8) Data shown are the mean±SEM of six dogs for each treatment. FECT and statistical procedures are described in Methods. A statistically significant prazosin dose-dependent increase in elapsed time and number of attacks was obtained (P < 10-9). (1), P < 0.05 vs. placebo; (2), P < 0.01 vs. placebo; (3), P < IO-' vs. placebo; (4), P < 106 vs. placebo; (5), P < 10-vs. placebo; (6), P < 10-8 vs. placebo; (7), P < l0-4 VS. 0.5 mg/kg methoxamine; (8) , P < 10-vs. 0.5 mg/kg methoxamine.
floor, and partial in other cases (when the dog dropped to the ground on hindquarters, forequarters, or both, but with head above the floor). This test has been used previously with poodles and Dobermans and is very sensitive to drugs known to modify human narcolepsy (8) .
Cardiovascular measurements. Systolic and diastolic BP (SBP and DBP) and HR were measured directly by an auscultatory method comparable to that described in reference 20. The dogs were trained to stand quietly in a sling that supports most of their weight and did not show cataplexy during the measurements. BP was taken on the forelimb after detection of the humeral artery pulse. HR was taken by thoracic auscultation. Materials used included a child-size cuff, a diaphragm-type stethoscope, and a standard sphygmomanometer. (mean+SEM) . Similarly, the time spent in cataplexy during the locomotor activity procedure was correlated with its corresponding number of attacks during the same drug-free tests (n = 150, r2 = 0.184, P < l0-7). The drug-free number of attacks during FECT (elicited cataplexy) was also slightly correlated with the time spent in cataplexy during the locomotor activity test (spontaneous cataplexy) (n = 150, r2 0.035, P < 0.05).
Effect ofprazosin on the cataplexy ofhomozygous Dobermans. The first compound tested on cataplexy was prazosin, a very selective alpha-l adrenergc receptor antagonist (22, 23) that easily crosses' the blood brain barrier (24) . Prazosin tested. Prazosin even triggered attacks in the oldest animal of our group, who normally showed no cataplexy during FECT. The dose dependence of the effect of prazosin on FECT was calculated on the mean of the three postdrug data points collected after various doses of prazosin (2.5-600 Ag/kg). This mean effect is shown on Fig. 1 . A high correlation was obtained between the effect of prazosin on the number of attacks or the elapsed time and the logarithm of the prazosin dose [number of attacks vs. log (dose of prazosin): n = 36 (six dogs X six doses), r2 = 0.760, P < 10-9; elapsed time vs. log (dose of prazosin): n = 36, r2 = 0.702, P < 10-9]. Estimations of the maximal effects and ED50 for the number of attacks were E.
= 12.49 attacks, ED50 = 73.55 ,ug/kg (correlation between parameters estimates r = 0.787, n = 36) and for elapsed time were Ema = 159.9 s, ED50 = 97.61 ug/kg (correlation between parameters estimates r = 0.800, n = 36). Prazosin was also able to increase the number of cataplectic attacks and the time spent in cataplexy during simple observation without emotional stimuli (locomotor activity measurements, Table II ).
The drug also produced a significant decrease in the number of line crossings by the narcoleptic dogs during the locomotor activity test (Table II) , but the effect disappeared when the number of crossings was corrected for the time the dogs were awake (Table II) . A correlation was obtained between the effect of a given dose of prazosin on the number of attacks or the time spent in cataplexy during the locomotor activity test and (Table III) . The magnitude of changes appeared similar in the three groups of animals (homozygous, heterozygous, and control dogs) (Table III) .
Effect ofprazosin on FECT in control and heterozygous Dobermans. Prazosin had a noticeable effect on BP (see above) and control experiments were then needed to eliminate the role of the cardiovascular system in the effect observed on FECT. Control and heterozygous Dobermans did not present any spontaneous or emotionally induced cataplectic attacks and were able to eat all the pieces offood in < 20 s (Table I and   II) . Prazosin, at a dose of 600 jig/kg (7 to 20 times the ED5O in narcoleptic dogs), did not produce any cataplectic attacks in these normal dogs, despite the fact that potent vasodilation and hypotension were observed (Table III) Placebo, prazosin (Pz), and hydralazine were given per os just after the baseline testing (t = 0 h). Metaraminol was injected intramuscularly I h after the first testing. Comparisons between groups were made using analysis of variance. Statistical procedures are described in detail in Methods. Number of attacks: P < 10-7 prazosin vs. placebo; P < 0.05 hydralazin vs. placebo; P < 10-6 Pz + metaraminol vs. metaraminol. Elapsed time: P < 10-7 prazosin vs. (Table IV) and did not change cataplexy (Fig. 2) , demonstrating that peripheral alpha-i stimulation does not explain the beneficial effects of methoxamine. We also tried to dissociate the central from the peripheral alpha-I effects by administering prazosin in the absence and presence of metaraminol to counteract the hypotensive effect of prazosin (25) . The two drug regimens effectively normalized the blood pressure (Table IV) , whereas the aggravation of spontaneous and food-elicited cataplexy induced by prazosin persisted (Fig. 2 , Table V ). These results demonstrate that the peripheral cardiovascular effects have little participation in the overall anticataplectic effect of the centrally acting drugs described in this work. A last control experiment examined the effect of another potent hypotensive agent, hydralazine (29), on cataplexy. Administration of hydralazine induced hypotension and tachycardia (Table IV) without large changes in cataplexy (Fig. 2) . A statistically significant improvement was even noticed after hydralazine administration (Fig. 2) .
Effect ofmethoxamine alone and associated with prazosin.
Methoxamine was selected as a central alpha-I receptor agonist because it crosses the blood brain barrier (13) and has been reported to have some effect on REM sleep (14, 30). Methoxamine also has some other pharmacological properties, such as a beta-blocking action (27) , which cannot be neglected in vivo. Methoxamine improved number of attacks and elapsed time on the FECT when administered at 0.5 mg/kg i.m. (Table I) . A combination of methoxamine (0.5 mg/kg i.m.) and prazosin (600 ,ag/kg p.o.) did not modify blood pressure and HR (Table   III) , but did increase elicited and spontaneous cataplexy similar to that obtained with prazosin alone (Table I and II), confirming the alpha-I mediation of the methoxamine effect (Tables I and II) . Effect ofdextroamphetamine, nisoxetine, and protriptyline alone and associated with prazosin. Dextroamphetamine alone significantly decreased cataplexy during FECT (Fig. 3) , increased locomotor activity (number of crossings, even when corrected for the time spent in cataplexy and sleep/number of crossings by minute of wake) (Table V) and produced systolic hypertension (Table IV) . Nisoxetine and protriptyline also decreased food-elicited cataplexy (Fig. 3) but did not change cardiovascular parameters and locomotor activity significantly (Table IV and V) . Dextroamphetamine, nisoxetine, or protriptyline when combined with prazosin (600 ,ug/kg p.o.) produced a large increase of spontaneous and elicited cataplexy similar to the one obtained with prazosin alone (Fig. 3 , Table  V) . Coadministration of dextroamphetamine with prazosin also reduced the hypotension produced by the alpha-I blocking agent (Table IV) .
Effect ofprazosin in combination with atropine and methylatropine. As expected from the literature, atropine, which crosses the blood-brain barrier, ameliorated food-elicited cataplexy (Fig. 4, Table V ), whereas methylatropine, a peripheral anticholinergic drug, was ineffective on FECT (Fig. 4) . Both compounds produced tachycardia but did not modify significantly SBP or DBP (Table IV) . The aggravating effect of prazosin (600 ,g/kg p.o.) on elicited and spontaneous cataplexy was completely abolished by a coadministration of atropine (Fig. 4, Table V ) and the combination of both drugs even improved the dogs, as did atropine alone (Fig. 4) . On the other hand, methylatropine, when associated with prazosin, did not modify the prazosin effect, and the combination of both drugs aggravated the dogs, as did prazosin alone (Fig. 4) . Atropine and methylatropine both produced a similar tachycardia when associated with prazosin (Table IV) .
Discussion
Alpha-i adrenoceptors are widely distributed within the central nervous system (31), but little is known about their physiological role. Alpha-I adrenergic agents have no overt central effects in waking animals (26, 32, 33) and humans (34) , and reports conffict over their effects on REM sleep (12) (13) (14) (15) (16) 30 ). Our data demonstrate a crucial role of these receptors in canine narcolepsy, which is considered an animal model of human narcolepsy.
The canine disorder, documented since 1973, presents striking clinical similarities to its human counterpart. The animals have been shown to be abnormally sleepy (18, 19) and to have fragmented sleep/wake patterns (19) . Furthermore, the dogs show loss of muscle tone during feeding, playing, or sex- We also antagonized the effect of some classical nonspecific therapeutic agents (amphetamine, protriptyline, and nisoxetine) with prazosin, suggesting that, as proposed in the rationale of the study, these drugs could improve narcolepsy by a presynaptic increase in central noradrenergic activity, which'then stimulates alpha-I receptors.
The importance of pontine central cholinergic transmission in REM sleep regulation has been extensively investigated by general pharmacology and local brainstem stimulation (2) (3) (4) (5) (6) (7) . Cholinergic neurons of the dorsal pontine tegmentum tonically inhibit muscle tone during REM sleep (2-3, 7). Consistent with these anatomical findings, central cholinergic stimulation by physostigmine or arecoline has been reported to aggravate the symptoms in narcoleptic dogs, whereas central anticholinergic drugs, such as atropine or scopolamine, improve them (8) . This well-known effect of atropine is shown in Fig. 4 Figure 4 . Effect of placebo, atropine (0.1 mg/kg i.m.), and methylatropine (0.1 mg/kg i.m.) alone and in combination with prazosin (600 ug/kg p.o.) on cataplexy in narcoleptic Dobermans. Prazosin (Pz) was administered just after the first test. Atropine and methylatropine were given 1 h after the first testing. Data are the mean of six dogs for each treatment. Methods are described in the legend to Fig.  1 and in the text. Number of attacks: P < 10-7 prazosin vs. placebo; P < 0.05 atropine vs. placebo; P < 10' Pz + atropine vs. prazosin; P < 0.001 Pz + methylatropine vs. methylatropine. Elapsed time: P < 10-7 prazosin vs. placebo; P < lo-8 Pz + atropine vs. prazosin; P < 0.01 Pz + methylatropine vs. methylatropine. I, prazosin; A, placebo; tr , atropine; -b , pz + atropine; ...* m --, methylatropine; * * * + * * *, pz + methylatropine.
anticholinergic drug, does not modify FECT (Fig. 4) . Ifalpha-I adrenergic receptors are mainly implicated in narcolepsy, one may ask whether these mechanisms are integrated with these cholinergic mechanisms (i.e., does the monoaminergic system control the cholinergic system or do both systems work in parallel and independently?). To answer this question, we examined the coadministration of prazosin with both atropine and methylatropine, to rule out any peripheral interaction. Atropine, but not methylatropine, completely suppressed the effects of prazosin (Fig. 4) . The 
